Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gastrointestinal 2Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 2Triple Negative Breast Neoplasms 1Treatment for Metastatic or Locally Advanced Cervical Cancer 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Colonic Neoplasms 1Advanced Endometrial Cancer 1

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × NVP-BKM120 × Gynecologic × Clear all
NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Array BioPharma

Phase 1 Completed
89 enrolled
BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡